David J. Morris, MRCPath
This content is PDF only. Please click on the PDF icon to access.
To the editor: In two recent trials, the mortality from cytomegalovirus pneumonia was lower in recipients of bone marrow allografts given combined ganciclovir and cytomegalovirus immune globulin therapy than in historical controls given no therapy or either agent alone (1, 2). These results were considered to indicate that combined therapy is more efficacious than ganciclovir or immune globulin therapy alone. Another explanation of the results is that ganciclovir therapy is more likely to be effective when commenced early in the course of cytomegalovirus pneumonia (3). Neither study established that the severity of the pneumonia was similar at the initiation of
Morris DJ. Ganciclovir and Immune Globulin in Cytomegalovirus Pneumonia. Ann Intern Med. 1989;110:575. doi: https://doi.org/10.7326/0003-4819-110-7-575_1
Download citation file:
Published: Ann Intern Med. 1989;110(7):575.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use